DEPLOYDatabase

Company

Moon Surgical

surgical robotmoonsurgical.com

Surgical-robotics company (Paris + San Carlos CA; CEO Anne Osdoit, chair Fred Moll) making the Maestro laparoscopic surgical-assistant robot with the shipped…

Track Moon Surgical
Founded
2020
HQ
San Carlos, California, USA
Status
private (~$90M+ raised; NVentures-backed)

The verified answer

As of Sep 2026, DEPLOY verifies Moon Surgical: 1 model, 1 deployment across 1 region, $98.0M raised. 4 sources back the record.

Regulatory status2 FDA 510(k) clearances

Moon Surgical holds 2 FDA 510(k) clearances, per the DEPLOY registry.

See all 2 filings

CategorySurgical robots

Funding

$98.0M

Models

1

Deployments

1

Overview

Surgical-robotics company (Paris + San Carlos CA; CEO Anne Osdoit, chair Fred Moll) making the Maestro laparoscopic surgical-assistant robot with the shipped FDA-cleared ScoPilot AI (Nvidia Holoscan).

Verified record

Verified deployments
1 deployment on file
Active incidents
None on file

Valuation of record

DEPLOY VERIFIED
$656M (reported, approximate)as of Jan 2023

Priced roundSeries B post-money

See the full valuations ranking →

Key facts

Product

Maestro laparoscopic surgical-assistant robot + ScoPilot shipped AI scope-control.

Gating events

Maestro FDA 510(k) K240598 Jun 5 2024; ScoPilot FDA-cleared 2025 with PCCP.

CEO

Anne Osdoit

Chair

Fred Moll

Additional office location

Paris, France

ScoPilot AI platform

NVIDIA Holoscan

Data & sources

Press releases

1

Government records

1

Web sources

2

4 sources backing this record.View all →

Models (1)

View all models →

Current platform

Maestro

Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair and backers including Sofinnova Partners and NVIDIA's venture arm NVentures) makes Maestro, a laparoscopic surgical-assistant and collaboration robot that holds and positions instruments and the endoscope alongside the surgeon rather than acting as a full master-slave teleoperation console, targeting the large pool of soft-tissue procedures unserved by teleoperated robots. The commercial Maestro received FDA 510(k) clearance under K240598 on June 5, 2024, and the company reports more than 1,100 patients treated across the US and Europe, on roughly $90 million-plus in funding. A notable AI distinction in this cohort: Maestro's ScoPilot is a genuinely shipped, FDA-cleared AI feature for intraoperative scope control, powered by NVIDIA Holoscan and cleared with a Predetermined Change Control Plan, rather than a mere demonstration, which sets Maestro apart from the teleoperation-only platforms here. A pathway correction worth recording: Maestro went the 510(k) route under K240598, not the de novo route sometimes assumed, with the contemporaneous de novo authorizations belonging to different companies such as Virtual Incision and MMI. The registry records Maestro at commercial maturity, an early-commercial collaborative-assist robot past its gating event, while noting that its CE mark status, exact installed-system count, and the more-than-1,100-patients figure are not independently verified.

surgicalView model →

Moon Surgical on the deployment map

View the global map

1 verified deployment across 1 region, newest verified Sep 2023. Explore where Moon Surgical's robots are operating, by place and type.

Free to use on your site, with a link back to DEPLOY.

View the full Moon Surgical deployment record →

Free to use on your site, with a link back to DEPLOY.

Relationships

SSofinnova PartnersInvestorOOrbiMedInvestorSSectoral Asset ManagementInvestorMMoon SurgicalCustomer

Explainers

Plain-language answers to the questions people ask about Moon Surgical, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.Read the full explainer →
What is Moon Surgical Maestro?
Moon Surgical Maestro is the Maestro Laparoscopy Co-Pilot, an FDA-cleared ASSISTIVE (NOT replacement) robotic system for laparoscopic procedures from Moon Surgical, a French-US dual-base company founded 2020. Per DEPLOY's surgical cluster framework: FDA 510(k) K240598 cleared June 2024 (primary-source FDA database verification). EDITORIAL DISTINCTION: assistive-laparoscopy positioning. Maestro augments surgeons within existing laparoscopic procedures rather than replacing them as full surgical platforms (Intuitive da Vinci, Medtronic Hugo, CMR Versius, J&J Ottava). Smaller-footprint OR integration + commercial-niche positioning. Per DEPLOY's surgical cluster framework, Maestro is the cohort's genuine shipped assistive-AI exemplar within the broader replacement-robotics cluster. Cohort positioning: assistive-laparoscopy commercial-niche archetype within the surgical cluster, extending the cluster's structural axes from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance (Wave 2).Read the full explainer →
Which surgical robot is most deployed?
Intuitive Surgical's da Vinci: 11,106 systems installed worldwide as of Dec 31, 2025 per its 10-K, roughly an order of magnitude ahead of every soft-tissue competitor. Stryker Mako is the only credible challenger on procedure volume, via orthopedics.Read the full explainer →

Current leadership (2)

Founders (2)

See all founders across the registry →

Board (1)

Safety record

No incidents on record for Moon Surgical.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Operator customers (1)

Recent coverage

Moon Surgical in third-party press

Moon Surgical wins first FDA 510(k) clearance for surgical robot

Jun 25, 2026

Moon Surgical wins FDA clearance for Maestro

Jun 1, 2025

Peers

42 peers across 1 segment. Every Moon Surgical competitor derived from shared form-factor and application-domain edges.

surgical robot(42)

28 companies in this segment · moderately_concentrated (HHI 2056.2102191459944) · leader Mazor Robotics at 3317%